How much funding has BioAtla raised?

BioAtla has raised $72.5M in total funding, most recently a Series D round.

Who are BioAtla's investors?

BioAtla's investors include Soleus Capital, HBM Healthcare Investments, Cormorant Asset Management, Pfizer Ventures.

Where is BioAtla headquartered?

BioAtla is headquartered in San Diego, California, United States.

What industry is BioAtla in?

BioAtla operates in Biotech, Healthcare.

BioAtla

IPO

San Diego, United States · Founded 2007 · $72.5M raised

Biotech

Healthcare

Headquarters: San Diego, California
Founded: 2007
Business Model: B2B
Website: bioatla.com

Total Funding: $72.5M
Last Round: $72.5M Series DJul 2020
Rounds: 1

About

BioAtla is a San Diego biotech company that develops novel monoclonal antibody and cell-based therapeutics using its proprietary Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!) platforms. These technologies, protected by more than 700 issued patents and patent applications, allow the company to develop novel biologics that are safer and more effective by more selectively targeting cancer tissue and improving manufacturability. Improved selectivity for the tumor microenvironment expands the universe of potential drug targets, enabling treatment of previously untreatable cancers.

Summary

BioAtla is a Biotech company based in San Diego, United States, founded in 2007. It has raised $72.5M in total across 1 round, most recently a $72.5M Series D round in Jul 2020. Investors include Soleus Capital, HBM Healthcare Investments and Cormorant Asset Management.